Rituximab for the Treatment of Wegener’s Granulomatosis and Microscopic Polyangiitis

checkorphan
Learn more about:
Wegener’s Granulomatosis
Related Clinical Trial
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Hydroxychloroquine in ANCA Vasculitis Evaluation Vasculitis Illness Perception (VIP) Study Reproductive Health in Men and Women With Vasculitis Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Impact of Vasculitis on Employment and Income Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases VCRC Tissue Repository Yellow Fever Vaccine in Patients With Rheumatic Diseases Journey of Patients With Vasculitis From First Symptom to Diagnosis One-Time DNA Study for Vasculitis Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Clinical Transcriptomics in Systemic Vasculitis (CUTIS) The ANCA Vasculitis Questionnaire (AAV-PRO©) Vasculitis Pregnancy Registry VCRC Patient Contact Registry Patient-Reported Data Validation Study Educational Needs of Patients With Systemic Vasculitis Diagnostic Effectiveness of Virtual Bronchoscopy Alemtuzumab for ANCA Associated Refractory Vasculitis Interventional Cryotherapy for the Eradication of Benign Airway Disease (“ICE the BAD”) PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Plasma Exchange for Renal Vasculitis PRO Development for ANCA Associated Vasculitis BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Rituximab Vasculitis Maintenance Study Anti-Cytokine Therapy for Vasculitis Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Low-dose Glucocorticoid Vasculitis Induction Study Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. The Assessment of Prednisone In Remission Trial (TAPIR) – Patient Centric Approach Steroids and Methotrexate to Treat Systemic Vasculitis Efficacy Study of Two Treatments in the Remission of Vasculitis Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography The Assessment of Prednisone In Remission Trial – Centers of Excellence Approach Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener’s) Rituximab for the Treatment of Wegener’s Granulomatosis and Microscopic Polyangiitis Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener’s) and Microscopic Polyangiitis Mycophenolate Mofetil for Treatment of Relapses of Wegener’s Disease or Microscopic Polyangiitis (MPA) Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Daclizumab to Treat Wegener’s Granulomatosis An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener’s Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies Etanercept to Treat Wegener’s Granulomatosis Treatment of Wegener’s Granulomatosis With Cyclophosphamide Mycophenolate Mofetil to Treat Wegener’s Granulomatosis and Related Vascular Inflammatory Conditions Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener’s Granulomatosis Comparison of Treatments to Maintain Disease Remission in Patients With Wegener’s Granulomatosis and Related Vasculitis Syndromes Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener’s Granulomatosis) Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study Analysis of Bronchial Tissue and Fluid in Patients With Wegener’s Granulomatosis TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Study of One Protein Implicated in Wegener Disease Abatacept in Treating Adults With Mild Relapsing Wegener’s Granulomatosis Phase II Study on Gusperimus in Patients With Refractory Wegener’s Granulomatosis Etanercept for Wegener’s Granulomatosis Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener’s Granulomatosis

Brief Title

Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis

Official Title

Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI)

Brief Summary

      Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of
      small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's
      granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used
      to treat certain types of cancer. The purpose of this study is to determine the effectiveness
      of rituximab in treating patients with WG and MPA.

      Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce
      disease remission by Month 6.

Detailed Description

      Current conventional therapies for ANCA-associated vasculitis (AAV) are associated with high
      incidences of treatment failure, disease relapse, substantial toxicity, and patient morbidity
      and mortality. Rituximab is a monoclonal antibody used to treat non-Hodgkin's lymphoma. This
      study will evaluate the efficacy of rituximab with glucocorticoids in inducing disease
      remission in patients with severe forms of AAV (WG and MPA).

      The study consists of two phases: a 6-month remission induction phase, followed by a 12-month
      remission maintenance phase. All participants will receive at least 1 g of pulse intravenous
      methylprednisolone or a dose-equivalent of another glucocorticoid preparation. Depending on
      the participant's condition, he or she may receive up to 3 days of intravenous
      methylprednisolone for a total of 3 g of methylprednisolone (or a dose-equivalent). During
      the remission induction phase, all participants will receive oral prednisone daily (1
      mg/kg/day, not to exceed 80 mg/day). Prednisone tapering will be completed by the Month 6
      study visit.

      Next, participants will be randomly assigned to one of two arms. Arm 1 participants will
      receive rituximab (375 mg/m^2) infusions once weekly for 4 weeks and cyclophosphamide (CYC)
      placebo daily for 3 to 6 months. Arm 2 participants will receive rituximab placebo infusions
      once weekly for 4 weeks and CYC daily for 3 to 6 months. During the remission maintenance
      phase, participants in Arm 1 will discontinue CYC placebo and start oral azathioprine (AZA)
      placebo daily until Month 18. Participants in Arm 2 will discontinue CYC and start AZA daily
      until Month 18. Participants who fail treatment before Month 6 will be crossed over to the
      other treatment arm unless there are specific contraindications. Participants in either group
      who reach clinical remission before they complete 6 months of therapy may switch from
      CYC/placebo to AZA/placebo if directed by their physicians.

      All participants will be followed for at least 18 months. Initially, study visits are weekly,
      progressing to monthly and then quarterly visits as the study proceeds. Blood collection will
      occur at each study visit.

Study Phase

Phase 2/Phase 3

Study Type

Interventional

Primary Outcome

Disease Remission

Secondary Outcome

 Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy

Condition

Vasculitis

Intervention

Rituximab plus cyclophosphamide placebo (rituximab group)

Study Arms / Comparison Groups

 Rituximab
Description:

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Drug

Estimated Enrollment

197

Start Date

January 2005

Completion Date

January 2010

Primary Completion Date

December 2008

Eligibility Criteria

        Inclusion Criteria:

          -  Weight of at least 88 pounds(40 kilograms)

          -  Diagnosis of Wegener's granulomatosis or microscopic polyangiitis according to the
             definitions of the Chapel Hill Consensus Conference

          -  Newly diagnosed patient of Wegener's granulomatosis or microscopic polyangiitis OR
             must be experiencing a disease flare characterized by: (a) active disease with a
             Birmingham Vasculitis Activity Score for Wegener's granulomatosis (BVAS/WG) of 3 or
             greater that would normally require treatment with CYC; OR (b) disease severe enough
             to require treatment with CYC; OR (c) must be positive for either PR3-ANCA (ANCA
             directed against proteinase 3) or MPO-ANCA (ANCA directed against myeloperoxidase)at
             the screening

          -  Willing to use acceptable forms of contraception for the duration of the study and for
             up to 1 year after stopping study medications

          -  Willing to report pregnancies (female participants or male participants' partners)
             occurring at any time during the study and for up to 1 year after stopping study
             medications

          -  Parent or guardian willing to provide informed consent, if applicable

        Exclusion Criteria:

          -  Diagnosis of Churg-Strauss Syndrome according to the definitions of the Chapel Hill
             Consensus Conference

          -  Have limited disease that would not normally be treated with CYC

          -  Requires mechanical ventilation because of alveolar hemorrhage

          -  History of severe allergic reactions to human or chimeric monoclonal antibodies

          -  Active systemic infection

          -  Have a deep-space infection, such as osteomyelitis, septic arthritis, or pneumonia
             complicated by pleural cavity or lung abscess, within 6 months prior to study entry

          -  History of or current hepatitis B or C infection

          -  HIV (human immunodeficiency virus) infected

          -  Acute or chronic liver disease that, in the opinion of the investigator, may interfere
             with the study

          -  History of or active cancer diagnosed within the last 5 years. Individuals with
             squamous cell or basal cell carcinomas of the skin and individuals with cervical
             carcinoma in situ who have received curative surgical treatment may be eligible for
             this study.

          -  History of anti-glomerular basement membrane (anti-GBM) disease

          -  Other uncontrolled disease, including drug and alcohol abuse, that may interfere with
             the study

          -  Pregnancy or breastfeeding

Gender

All

Ages

15 Years - N/A

Accepts Healthy Volunteers

No

Contacts

John H. Stone, MD, MPH, ,

Location Countries

Netherlands

Location Countries

Netherlands

Administrative Informations

NCT ID

NCT00104299

Organization ID

DAIT ITN021AI

Responsible Party

Sponsor

Study Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

 Immune Tolerance Network (ITN)

Study Sponsor

John H. Stone, MD, MPH, Study Chair, Johns Hopkins University

Verification Date

March 2017